[{"id":"2f454d62-b561-48df-9aa8-c95f396adca9","acronym":"VOLFI","url":"https://clinicaltrials.gov/study/NCT01328171","created_at":"2021-01-18T05:24:48.418Z","updated_at":"2024-07-02T16:35:45.737Z","phase":"Phase 2","brief_title":"FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)","source_id_and_acronym":"NCT01328171 - VOLFI","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" EGFR • KRAS • PIK3CA • NRAS • PTEN • ERCC1 • RAS • MTHFR","pipe":" | ","alterations":" EGFR mutation • PIK3CA mutation • KRAS wild-type • RAS wild-type • EGFR exon 18 mutation • KRAS exon 2 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["EGFR • KRAS • PIK3CA • NRAS • PTEN • ERCC1 • RAS • MTHFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PIK3CA mutation • KRAS wild-type • RAS wild-type • EGFR exon 18 mutation • KRAS exon 2 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2023-06-14"}]